As monotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC expressing PD-L1 (Tumor Proportion Score ≥1%), with no EGFR or ALK genomic tumor aberrations. This evidence concerns the gene ALK and neoplasm.